Pioneering targeted therapies for global patient needs
We develop innovative biologics with a focus on oncology, cardiovascular and metabolic diseases, immunology, and ophthalmology. By pairing deep biological insights with advanced antibody engineering, we design investigational precision therapies toward addressing unmet medical challenges, from first-in-class bispecifics to optimized ADCs.
Active Development
Name (Target)
Therapeutic Area
DiscoveryIND-EnablingPhase 1Phase 2Phase 3
IBI363
Target
PD-1/IL-2α-bias
Therapeutic Area
Oncology
Development Stage
Phase 3
IBI363 is a PD-1/IL-2 alpha-biased bispecific antibody fusion protein, currently in clinical development for non-small cell lung cancer (Phase 3, 2L Sq), colorectal cancer (Phase 2), and other solid tumors (Phase 1).
Partnered with Takeda Pharmaceutical Company. Takeda will lead global co-development and U.S. co-commercialization and has exclusive commercial rights outside the U.S. and mainland China, Hong Kong, Macau and Taiwan.
IBI343
Target
Claudin18.2 ADC
Therapeutic Area
Oncology
Development Stage
Phase 3
IBI343 is a Claudin18.2-targeting antibody–drug conjugate with a topoisomerase I inhibitor payload, currently in clinical development for gastric cancer (Phase 3, third-line) and pancreatic ductal adenocarcinoma (Phase 1/2).
Partnered with Takeda Pharmaceutical Company. Takeda has development and commercialization rights for the treatment worldwide outside of mainland China, Hong Kong, Macau and Taiwan.
IBI308
Target
PD-1
Therapeutic Area
Oncology
Development Stage
Phase 3
IBI308 is a PD-1-targeting monoclonal antibody, currently in Phase 3 clinical development for multiple solid tumors and hematologic malignancies.
IBI354
Target
HER2
Therapeutic Area
Oncology
Development Stage
Phase 3
IBI354 is a HER2-targeting antibody-drug conjugate, currently in Phase 3 clinical development for HER2-positive breast cancer and platinum-resistant ovarian cancer.
IBI310
Target
CTLA-4
Therapeutic Area
Oncology
Development Stage
Phase 1
IBI310 is a CTLA-4-targeting monoclonal antibody, currently in Phase 1/2 clinical development for solid tumors.
IBI3009
Target
DLL3 (protein delta-like ligand 3) ADC
Therapeutic Area
Oncology
Development Stage
Phase 1
IBI3009 is a DLL3-targeting antibody–drug conjugate, currently in Phase 1 clinical development for small cell lung cancer.
Partnered with Roche.
IBI3001
Target
B7-H3/EGFR
Therapeutic Area
Oncology
Development Stage
Phase 1
IBI3001 is a bispecific antibody–drug conjugate targeting B7-H3 and EGFR in clinical development for the treatment of solid tumors.
IBI3003
Target
BCMA / GPRC5D / CD3
Therapeutic Area
Oncology
Development Stage
Phase 1
IBI3003 is a BCMA/GPRC5D/CD3 tri-specific antibody, currently in Phase 1/2 clinical development for relapsed or refractory multiple myeloma.
IBI3020
Target
CEACAM5
Therapeutic Area
Oncology
Development Stage
Phase 1
IBI3020 is a CEACAM5-targeting dual-payload antibody-drug conjugate, currently in Phase 1/2 clinical development for treatment-resistant tumors.
IBI3014
Target
TROP2 / PD-L1
Therapeutic Area
Oncology
Development Stage
Phase 1
IBI3014 is a TROP2/PD-L1 bispecific antibody-drug conjugate, currently in Phase 1 clinical development for advanced solid tumors.
In Discovery
Name (Target)
Therapeutic Area
DiscoveryIND-EnablingPhase 1Phase 2Phase 3
3 Non-disclosed
Target
Multiple Targets
Therapeutic Area
Various
Development Stage
Discovery
Fortvita, the global development arm of Innovent Biologics, collaborates with leading biopharmaceutical partners to accelerate the development of innovative therapies and bring next-generation treatments to patients worldwide.
For additional details on the broader pipeline, please refer to publicly available information from Innovent Biologics.
Careers
We’re always looking for talented individuals to join our team
If you enjoy tackling complex problems, collaborating across disciplines, and driving real-world impact, we want to hear from you. Explore open positions and join us in writing the next chapter of therapeutic innovation.
